We are live on ! Find out more
TRIB

Trinity Biotech

82 hedge funds and large institutions have $205M invested in Trinity Biotech in 2015 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 21 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 21

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

3% less capital invested

Capital invested by funds: $212M → $205M (-$6.89M)

11% less funds holding

Funds holding: 9282 (-10)

38% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 24

99% less call options, than puts

Call options by funds: $2K | Put options by funds: $169K

Holders
82
Holders Change
-10
Holders Change %
-10.87%
% of All Funds
2.15%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
15
Increased
36
Reduced
21
Closed
24
Calls
$2K
Puts
$169K
Net Calls
-$167K
Net Calls Change
+$19K

TRIB Hedge Fund Activity: Q4 2015 in Review

82 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2015, worth a combined $205M — down 3.3% from $212M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of TRIB and 15 opened new positions — a net loss of 9 holders — while 21 trimmed existing stakes and 36 added.

The largest buyer was Bank of Montreal, opening a new position worth an estimated $13.1M. The largest seller was Cardinal Capital Management LLC (Connecticut), exiting entirely with an estimated $9.71M sold.

  • 82 institutional investors held Trinity Biotech (TRIB) as of Q4 2015, down from 92 in Q3 2015.
  • Funds reported $205M of Trinity Biotech stock for Q4 2015, down 3.3% quarter-over-quarter.
  • 15 funds opened new Trinity Biotech positions in Q4 2015 and 24 closed out, a net change of -9 holders.
  • The largest Trinity Biotech buyer in Q4 2015 was Bank of Montreal, an estimated $13.1M added.
  • The largest Trinity Biotech seller in Q4 2015 was Cardinal Capital Management LLC (Connecticut), an estimated $9.71M sold.

Based on aggregated 13F filings for Q4 2015.